ERISA Ledger · U.S. DOL EBSA Form 5500 (2024)

Theravance Biopharma U.s., INC.

Official 2024 U.S. DOL Form 5500 summary for Theravance Biopharma U.s., INC. (Theravance Biopharma U.s., INC. 401(k) Plan · EIN 46-3451245 · PN 001): $82.04M net assets, 99 active participants, and $4.33 per $10,000 (4.33 bps).

Reported Form 5500 Fee & Service Summary

Plan SponsorTheravance Biopharma U.s., INC.
Filing IdentifierTheravance Biopharma U.s., INC. 401(k) Plan · EIN 46-3451245 · PN 001
Plan Category & State401(k) Defined Contribution (CA)
Asset-Size Peer Cohort$25M-$100M
Plan Net Assets (2024)$82.04M
Active Participants99
Direct Admin Fee Rate$4.33 per $10,000 (4.33 bps)
Cohort Peer Median$19.23 per $10,000 (19.23 bps)
Primary Recordkeeper / ProviderMiller Kaplan Arase LLP
Schedule H Line 4a RemittanceTimely Employer Remittance (0 reported on Line 4a)

Browse all 78,373 plans & Schedule C vendors · Methodology · Meru AI